---
title: "The Hidden Epidemic: How Pediatric Bipolar Diagnosis Expanded—and Quietly Reversed"
description: "A sourced investigation of the fortyfold rise in youth bipolar office visits, disclosure sanctions, the Abbott Depakote resolution, DMDD, and what valproate evidence does and does not show."
author: "Bret Kerr"
organization: "ACRA Insight"
date: "2026-08-22"
canonical: "https://www.contextjamming.com/research/hidden-epidemic"
og_image: "https://www.contextjamming.com/HiddenEpidemic/hidden-epidemic-investigation-ledger.png"
keywords:
  - pediatric bipolar diagnosis
  - Depakote
  - valproate working memory
  - Joseph Biederman
  - Ellen Leibenluft
  - disruptive mood dysregulation disorder
  - Abbott Depakote settlement
  - AI drug repurposing
  - retrospective pharmacovigilance
  - AI for science
  - multi-model deep research
related:
  - url: https://x.com/BretKerr/status/2091358367507730748
    title: "The Fortyfold Decade"
  - url: https://www.contextjamming.com/about
    title: "About Bret Kerr and ACRA Insight"
  - url: https://www.contextjamming.com/research
    title: "Context Jamming Research"
---

# The Hidden Epidemic: How Pediatric Bipolar Diagnosis Expanded—and Quietly Reversed

**Published:** May 29, 2026

**Last reviewed:** August 22, 2026

**Author:** Bret Kerr / ACRA Insight (bret@acrainsight.com)

**Canonical:** https://www.contextjamming.com/research/hidden-epidemic

## Answer capsules

### Did pediatric bipolar disorder rise fortyfold?

No study measured a fortyfold rise in disease prevalence. Moreno and colleagues found that U.S. office visits in which a young person received a bipolar diagnosis rose from about 25 to 1,003 per 100,000 between 1994–95 and 2002–03; a visit is not a person, and one child can account for several visits. (https://pubmed.ncbi.nlm.nih.gov/17768268/)

### Did Harvard find scientific fraud by Joseph Biederman?

No. Harvard and Massachusetts General Hospital sanctioned Joseph Biederman, Thomas Spencer, and Timothy Wilens in 2011 for financial-disclosure violations; the sanctions were not a finding of scientific fraud, and no criminal charges were brought against the physicians. (https://www.npr.org/sections/health-shots/2011/07/02/137572941/harvard-punishes-3-psychiatrists-over-undisclosed-industry-pay)

### What did Abbott admit in the Depakote case?

Abbott Laboratories pleaded guilty in 2012 to a criminal misdemeanor for misbranding Depakote and entered a $1.5 billion criminal-and-civil resolution. The admitted criminal conduct concerned marketing the drug for agitation in elderly nursing-home dementia patients and for schizophrenia—not pediatric bipolar disorder. (https://www.justice.gov/archives/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote)

### Did Depakote work in the pediatric bipolar trial?

Depakote is FDA-approved for acute mania in adults. In a controlled trial of 150 patients ages 10 to 17, Depakote ER did not establish efficacy over placebo; that efficacy finding is a separate question from evidence of harm. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018723s060lbl.pdf)

### What did the severe mood dysregulation follow-up find?

Among 84 youths with severe mood dysregulation followed for a median of roughly 28 months, one developed a manic, hypomanic, or mixed episode; among 93 youths with narrowly defined bipolar disorder, 58 did. This is a group-level finding about diagnostic boundaries, not proof that any individual child was misdiagnosed. (https://pmc.ncbi.nlm.nih.gov/articles/PMC3000433/)

### Does valproate cause permanent working-memory injury?

A 2020 mini-review of ten studies in people with bipolar disorder found working memory was the cognitive domain most consistently affected among chronically treated patients. Only one included study was double-blind and quasi-randomized, so the review does not establish permanent cognitive injury or determine the cause of an individual patient’s symptoms. (https://www.sciencedirect.com/science/article/pii/S0165032719313515)

### What did DMDD change?

DSM-5 introduced disruptive mood dysregulation disorder in 2013 for children with persistent severe irritability and recurrent intense temper outbursts who do not show the distinct manic episodes required for bipolar disorder. It was a course correction built from a broad research debate, not a repudiation of one researcher. (https://www.nimh.nih.gov/health/publications/disruptive-mood-dysregulation-disorder)

### What is the AI-for-science argument behind this investigation?

Frontier AI can investigate drugs already in use by reading decades of labels, testimony, settlement documents, clinical trials, and neuroscience in adversarial multi-model loops. The stronger the models got, the less conspiratorial the surviving story became: every supported claim remained pinned to a record, and unsupported claims stayed marked as open questions. (https://x.com/BretKerr/status/2091358367507730748)

## Extractable claims

| What the record says | Primary source | The common misread |
|---|---|---|
| NAMCS-recorded office visits in which a youth received a bipolar diagnosis rose from about 25 to 1,003 per 100,000 between 1994–95 and 2002–03. Adult visits over the same period did not quite double. | [Moreno et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17768268/) · [NIMH trend summary](https://www.nimh.nih.gov/news/science-updates/2007/rates-of-bipolar-diagnosis-in-youth-rapidly-climbing-treatment-patterns-similar-to-adults) | That pediatric bipolar disorder itself rose fortyfold. A visit is not a person; one child with several visits is counted several times. |
| In 2011 Harvard and Massachusetts General Hospital sanctioned Joseph Biederman, Thomas Spencer, and Timothy Wilens for financial-disclosure violations following a 2008 Senate inquiry. | [Congressional Record](https://www.congress.gov/110/crec/2008/06/04/CREC-2008-06-04-pt1-PgS5029-2.pdf) · [NPR](https://www.npr.org/sections/health-shots/2011/07/02/137572941/harvard-punishes-3-psychiatrists-over-undisclosed-industry-pay) | That the institutions found scientific fraud. They did not, and no criminal charges were brought against the physicians. |
| In 2012 Abbott Laboratories pleaded guilty to a criminal misdemeanor for misbranding Depakote and entered a $1.5 billion criminal-and-civil resolution — $700 million in fine and forfeiture, $800 million civil, five years of probation. | [U.S. Justice Department](https://www.justice.gov/archives/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote) | That the admitted criminal conduct concerned pediatric bipolar disorder. DOJ's account centers on marketing Depakote for agitation in elderly nursing-home dementia patients, and on schizophrenia. |
| States reached a separate $100 million consumer-protection settlement with Abbott, reported as the largest of its kind against a drug maker. | [California DOJ release](https://oag.ca.gov/news/press-releases/attorney-general-kamala-d-harris-announces-national-settlements-abbott) | That this was a finding about pediatric use. It was a consumer-protection resolution. |
| Depakote is FDA-approved for acute mania in adults. In a controlled pediatric trial of 150 patients ages 10 to 17, Depakote ER did not establish efficacy over placebo. The prescribing information states this. | [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018723s060lbl.pdf) · [Wagner et al.](https://pubmed.ncbi.nlm.nih.gov/19325497/) | That failed efficacy is evidence of cognitive injury. It is an efficacy finding, and a separate question from harm. |
| Among 84 youths with severe mood dysregulation followed a median of roughly 28 months, one developed a manic, hypomanic, or mixed episode; among 93 youths with narrowly defined bipolar disorder, 58 did. (Leibenluft's 2011 review; the primary 2010 survival analysis reports 50 of 85.) | [Stringaris et al.](https://pmc.ncbi.nlm.nih.gov/articles/PMC3000433/) · [NIMH Leibenluft profile](https://www.nimh.nih.gov/news/science-updates/2018/nimh-director-joshua-gordon-and-irp-researcher-ellen-leibenluft-elected-to-the-national-academy-of-medicine) | That this retroactively proves any individual child was misdiagnosed. It is a group-level finding about diagnostic boundaries. |
| A 2020 mini-review of ten studies in people with bipolar disorder found working memory was the cognitive domain most consistently affected among chronically treated patients. Only one included study was double-blind and quasi-randomized. | [2020 cognition review](https://www.sciencedirect.com/science/article/pii/S0165032719313515) | That valproate is established to cause permanent cognitive injury. The review's own authors emphasize the limits; most structural findings come from epilepsy populations, some from case series of a half-dozen children. |
| DSM-5 introduced disruptive mood dysregulation disorder in 2013, giving chronically irritable children a category that does not require distinct manic episodes. | [NIMH guide to DMDD](https://www.nimh.nih.gov/health/publications/disruptive-mood-dysregulation-disorder) | That DMDD was a repudiation of any individual researcher. It was a course correction built from a broad research debate. |

Where a summary here and the sourced section text differ, the sourced section text and the linked primary record control.

## What this page does not claim

- That the fortyfold figure measures disease prevalence. It measures office visits.
- That any individual diagnosis was incorrect. No article can determine that; only a clinician reviewing the record can.
- That valproate caused permanent cognitive injury in adolescents treated psychiatrically. The structural findings come overwhelmingly from epilepsy populations.
- That a pediatric-cognition class action exists. As of the last review of public litigation trackers, none was identified.

## The open question

How many people entered long-term medication pathways during the pediatric bipolar expansion? How many would receive the same diagnosis under today's criteria? How many are still on those pathways twenty years later? And was anyone ever systematically recontacted and reassessed?

No epidemiology answers this. That absence is not a gap in the research — it is the finding.

## Stable anchors

- [AI for science thesis bridge](https://www.contextjamming.com/research/hidden-epidemic#ai-for-science)
- [AI for science heading](https://www.contextjamming.com/research/hidden-epidemic#ai-for-science-title)
- [Investigation ledger](https://www.contextjamming.com/research/hidden-epidemic#investigation-ledger)
- [Medical safety](https://www.contextjamming.com/research/hidden-epidemic#medical-safety)
- [Medical safety FAQ warning](https://www.contextjamming.com/research/hidden-epidemic#medical-safety-faq)
- [Research guide](https://www.contextjamming.com/research/hidden-epidemic#research-guide)
- [Fortyfold rise](https://www.contextjamming.com/research/hidden-epidemic#fortyfold-rise)
- [Joseph Biederman](https://www.contextjamming.com/research/hidden-epidemic#joseph-biederman)
- [Risperdal and Depakote](https://www.contextjamming.com/research/hidden-epidemic#risperdal-depakote)
- [Abbott and Depakote](https://www.contextjamming.com/research/hidden-epidemic#abbott-depakote)
- [Ellen Leibenluft](https://www.contextjamming.com/research/hidden-epidemic#ellen-leibenluft)
- [DMDD](https://www.contextjamming.com/research/hidden-epidemic#dmdd)
- [Timeline](https://www.contextjamming.com/research/hidden-epidemic#timeline)
- [Depakote evidence](https://www.contextjamming.com/research/hidden-epidemic#depakote-evidence)
- [Depakote working memory](https://www.contextjamming.com/research/hidden-epidemic#depakote-working-memory)
- [Depakote weight gain](https://www.contextjamming.com/research/hidden-epidemic#depakote-weight-gain)
- [Twice-exceptional](https://www.contextjamming.com/research/hidden-epidemic#twice-exceptional)
- [Legal status](https://www.contextjamming.com/research/hidden-epidemic#legal-status)
- [FAQs](https://www.contextjamming.com/research/hidden-epidemic#faqs)
- [FAQ heading](https://www.contextjamming.com/research/hidden-epidemic#faq-title)
- [Personal testimony](https://www.contextjamming.com/research/hidden-epidemic#personal-testimony)
- [Press resources](https://www.contextjamming.com/research/hidden-epidemic#press)
- [Press resources heading](https://www.contextjamming.com/research/hidden-epidemic#press-title)
- [Press contact and terms](https://www.contextjamming.com/research/hidden-epidemic#press-contact-title)
- [Standfirsts](https://www.contextjamming.com/research/hidden-epidemic#standfirst-title)
- [Verified press facts](https://www.contextjamming.com/research/hidden-epidemic#press-facts)
- [Verified press facts heading](https://www.contextjamming.com/research/hidden-epidemic#press-facts-title)
- [What this page does not claim](https://www.contextjamming.com/research/hidden-epidemic#press-not-claimed)
- [What this page does not claim heading](https://www.contextjamming.com/research/hidden-epidemic#not-claimed-title)
- [Open question](https://www.contextjamming.com/research/hidden-epidemic#open-question-title)
- [Assets and links](https://www.contextjamming.com/research/hidden-epidemic#assets-title)
- [Cite this page](https://www.contextjamming.com/research/hidden-epidemic#cite-this)
- [Citation heading](https://www.contextjamming.com/research/hidden-epidemic#cite-title)
- [Press medication safety](https://www.contextjamming.com/research/hidden-epidemic#medical-safety-press)
- [Source panel](https://www.contextjamming.com/research/hidden-epidemic#source-panel)
- [Source panel heading](https://www.contextjamming.com/research/hidden-epidemic#source-panel-title)

## Works cited

- [Quartz: Dario Amodei on trust and curing disease](https://qz.com/anthropic-dario-amodei-ai-backlash-trust-crisis-081726) — Reporting on the August 2026 trust argument cited by the thesis bridge.
- [Axios: Demis Hassabis role change](https://www.axios.com/2026/08/05/google-deepmind-demis-hassabis-ai) — Reporting on Hassabis becoming Chair of Google DeepMind and Chief Scientist of Alphabet.
- [The Fortyfold Decade on X](https://x.com/BretKerr/status/2091358367507730748) — The originating AI-for-science thesis thread.
- [Moreno et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17768268/) — The NAMCS office-visit trend study.
- [NIMH youth bipolar diagnosis trend summary](https://www.nimh.nih.gov/news/science-updates/2007/rates-of-bipolar-diagnosis-in-youth-rapidly-climbing-treatment-patterns-similar-to-adults) — NIMH's account of the study and treatment patterns.
- [Congressional Record: industry-payment inquiry](https://www.congress.gov/110/crec/2008/06/04/CREC-2008-06-04-pt1-PgS5029-2.pdf) — Senate record concerning disclosure of industry payments.
- [NPR: Harvard sanctions](https://www.npr.org/sections/health-shots/2011/07/02/137572941/harvard-punishes-3-psychiatrists-over-undisclosed-industry-pay) — Reporting on the 2011 institutional sanctions.
- [The New York Times: research center tied to drug company](https://www.nytimes.com/2008/11/25/health/25psych.html) — Reporting on the MGH research center and Johnson & Johnson.
- [Alliance for Human Research Protection: Biederman and Risperdal records](https://ahrp.org/biederman-j-j-risperdal-documents/) — Preserved documents concerning the research-center history.
- [U.S. DOJ: Abbott Depakote resolution](https://www.justice.gov/archives/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote) — The criminal plea and civil-resolution record.
- [California DOJ: national Abbott settlements](https://oag.ca.gov/news/press-releases/attorney-general-kamala-d-harris-announces-national-settlements-abbott) — The state consumer-protection settlement record.
- [DOJ: distribution of Abbott forfeiture proceeds](https://www.justice.gov/usao-wdva/pr/us-attorney-heaphy-announces-distribution-forfeiture-proceeds-commonwealth-s-attorneys) — The forfeiture-proceeds distribution record.
- [AbbVie/Abbott transaction filing](https://www.sec.gov/Archives/edgar/data/1551152/000104746912010903/a2209760zex-99_1.htm) — Corporate filing documenting the Abbott/AbbVie transaction.
- [Stringaris et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3000433/) — The severe mood dysregulation longitudinal analysis.
- [NIMH: Ellen Leibenluft profile](https://www.nimh.nih.gov/news/science-updates/2018/nimh-director-joshua-gordon-and-irp-researcher-ellen-leibenluft-elected-to-the-national-academy-of-medicine) — NIMH career and research summary.
- [NIMH guide to DMDD](https://www.nimh.nih.gov/health/publications/disruptive-mood-dysregulation-disorder) — NIMH's description of disruptive mood dysregulation disorder.
- [FDA prescribing information for Depakote](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018723s060lbl.pdf) — Indications, warnings, adverse effects, and pediatric trial findings.
- [Wagner et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19325497/) — Pediatric divalproex maintenance trial record.
- [TEAM study](https://pmc.ncbi.nlm.nih.gov/articles/PMC3581342/) — Comparative pediatric mania treatment findings.
- [VIRCD review](https://pubmed.ncbi.nlm.nih.gov/37515866/) — Review of valproate-induced reversible cognitive decline.
- [Pediatric brain-volume report](https://pubmed.ncbi.nlm.nih.gov/37565315/) — Pediatric structural findings cited with population limits.
- [2020 valproate cognition review](https://www.sciencedirect.com/science/article/pii/S0165032719313515) — Review of cognitive domains in chronically treated bipolar patients.
- [Randomized valproate weight study](https://pubmed.ncbi.nlm.nih.gov/18583434/) — Placebo-controlled weight findings in healthy adults.
- [Current DailyMed prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0dc024ce-efc8-4690-7cb5-639c728fccac&type=display) — Current drug-label information.
- [HHS medical-records guide](https://www.hhs.gov/hipaa/for-individuals/medical-records/index.html) — Federal guidance on access and amendment requests.
- [Drugwatch Depakote lawsuit tracker](https://www.drugwatch.com/depakote/lawsuits/) — Public litigation tracker reviewed for the legal-status section.
- [ClassAction.org Depakote tracker](https://www.classaction.org/depakote) — Public class-action tracker reviewed for the legal-status section.
- [BMJ disclosure inquiry report](https://pmc.ncbi.nlm.nih.gov/articles/PMC2427133/) — Peer-reviewed reporting on the disclosure inquiry.
- [Archived reporting snapshot BMreX](https://archive.ph/BMreX) — Preserved reporting record.
- [Archived reporting snapshot UqTJl](https://archive.ph/UqTJl) — Preserved reporting record.

## Press

**Byline:** Bret Kerr — ACRA Insight / Context Jamming

**Press contact:** bret@acrainsight.com

**On X:** https://x.com/BretKerr

**Terms:** Quote freely with a link to the canonical URL. No embargo. The author is available for interview, for background, and to share the underlying document set and the multi-model research methodology.

**Corrections:** Email the address above with the claim, the URL anchor, and the primary record. Corrections are made on the page and reflected in the last-reviewed date.

**Citation:** Kerr, Bret. "The Hidden Epidemic: How Pediatric Bipolar Diagnosis Expanded—and Quietly Reversed." Context Jamming, published May 29, 2026; last reviewed August 22, 2026. https://www.contextjamming.com/research/hidden-epidemic

## Safety note

Valproate should never be stopped abruptly. Nothing on this page is medical advice; medication changes require supervision by the clinician who manages the prescription.